Evidence map›Paper›PMID 24207133›Full record

ArticleEuropean urology2014

Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy.

Paras B Singh, Chukwuemeka Anele, Emma Dalton, Omar Barbouti, Daniel Stevens, Pratik Gurung, Manit Arya, Charles Jameson, Alex Freeman, Mark Emberton and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Paras B SinghDivision of Surgery and Interventional Sciences, University College London, London, UK.
Chukwuemeka AneleMedical School, University College London, London, UK.
Emma DaltonMedical School, University College London, London, UK.
Omar BarboutiMedical School, University College London, London, UK.
Daniel StevensNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Pratik GurungDivision of Surgery and Interventional Sciences, University College London, London, UK.
Manit AryaDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Barts Cancer Institute, Queen Mary, University of London, London, UK.
Charles JamesonDepartment of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK.
Alex FreemanDepartment of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK.
Mark EmbertonDivision of Surgery and Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Hashim U AhmedDivision of Surgery and Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: hashim.ahmed@ucl.ac.uk.
University College London · GBUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Oxford · GB

Funding

Medical Research Council G0701302Medical Research Council G1002509Prostate Cancer UK G2011/53Wellcome Trust
6 · The paper itself

Abstract

backgroundFocal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable.

objectiveTo determine the proportion of men with localised PCa who are potentially suitable for focal therapy. DESIGN, SETTING, AND

participantsOur institutional transperineal template prostate-mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identified 291 consecutive men with no prior treatment.

interventionTTPM biopsies using a 5-mm sampling frame. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. Binary logistic regression modelling was used to determine variables predictive for focal therapy suitability. RESULTS AND LIMITATIONS: The median age was 61 yr, and the median prostate-specific antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores. Of 239 of 291 men with cancer, 29% (70 men), 60% (144 men), and 8% (20 men) had low-, intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation (31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%, 61 men). Binary logistic regression modelling incorporating transrectal biopsy parameters showed no statistically significant predictive variable. When incorporating TTPM parameters, only T stage was a significant negative predictor for suitability (p=0.001) (odds ratio: 0.001 [95% confidence interval, 0.000-0.048]). Limitations of the study include potential selection bias caused by tertiary referral practise and lack of long-term results on focal therapy efficacy.

conclusionsFocal therapy requires an accurate tool to localise individual cancer lesions. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most of the men were suitable for a tissue preservation strategy.

Indexed as

Patient SelectionAblation TechniquesAdultAgedAged, 80 and overBiopsy, Fine-NeedleHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm GradingNeoplasm StagingProstateProstate-Specific AntigenProstatic NeoplasmsProstate-Specific AntigenBiopsyDiagnosisPathologyProstate cancerSurgeryTherapy

Identifiers

PMID24207133
PMCPMC4062939
OpenAlexW2123868969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.